OVARIA: AI-Driven Target Discovery for Ovarian Aging
Dr. Peter Fedichev
Menopause
Dr. Peter Fedichev
Menopause
Gero AI is a Series A biotech company headquartered in Singapore, using cutting-edge machine learning to discover novel drug targets and develop therapeutics against chronic diseases, with a core mission to slow human aging. Gero has established collaborations with leading institutions including Harvard Medical School, NYU, and the Roswell Park Cancer Center, and holds a strategic partnership with Pfizer to develop treatments for fibrotic diseases.
In partnership with AthenaBIO, Gero AI is re-analyzing ovarian aging Genome Wide Association Study (GWAS) data from the Estonian and UK Biobanks. This collaboration aims to identify at least 10 novel therapeutic targets, opening the door to both repurposed drug trials and the development of entirely new therapeutics in a space that has seen almost no innovation.
Women spend on average one third of their lives post-menopausal, yet today there is only one approved intervention, Hormone Replacement Therapy, which treats symptoms only, and is used by just 4% of women in the US. This project aims to change that.
Funding supports three core milestones over six months: (1) developing a Menopause Rating Scale from UK Biobank data, (2) training a Menopause Transition Risk model to identify high-risk cohorts, and (3) performing GWAS and rare variant association studies to identify novel ovarian aging targets.
Sign up to AthenaDAO newsletter and we'll keep you in the loop on the latest developments
